FDA expands approved use of Kalydeco for CF

On May 17, the U.S. Food and Drug Administration (FDA) expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis (CF), tripling the number of rage gene mutations the drug can now treat. Read more


Related Articles:

Leave a Reply

Your email address will not be published. Required fields are marked *

 

Shares